Senzime receives research grant from Bio-X

Uppsala, April 19, 2016. Senzime receives research grant from Vinnova through Bio-X, to conduct a study designed for clinical evaluation of OnZurf Probe and CliniSenz Analyzer for postoperative monitoring of patients with esophagus cancer. The grant also provides the ability to carry out activities prior to commercialization and CE marking of the products. The grant amounts to SEK 2 million, and the study will be conducted in Lund.

"Through blood tests, for example, lack of oxygen in the newly operated organ in some cases is detected after several days. Coupled with OnZurf Probe, our instruments CliniSenz Analyzer detect signs of this serious complication already after 20 minutes, which will result in significant patient benefit and reduced health care costs. We have previously conducted a clinical study where we monitored the blood sugar levels in patients at risk for diabetes. Now we will document the benefits of OnZurf Probe and CliniSenz Analyzer in patients with esophagus cancer, which is a large and growing patient population, and we will continue to seek partnerships to clinically document the benefits of our products, "says Lena Söderström, CEO of Senzime AB.

For further information, please contact:

Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email:

About Senzime
Senzime develops patient-oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. The company's share is listed on Aktietorget, Stockholm.

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime.


Documents & Links